A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)

KAYIKÇIOĞLU, LATİFE; Tokgozoglu, Lale; YILMAZ, MEHMET; Kaynar, Leylagul; Aktan, Melih; Durmus, Rana; Gokce, Cumali; Temizhan, Ahmet; ÖZCEBE, OSMAN; Akyol, Tulay; Okutan, Harika; Sag, Saim; Gul, Ozen; Salcioglu, Zafer; Yenercag, Mustafa; Altunkeser, Bulent; Kuku, Irfan; Yasar, Hamiyet; Kurtoglu, Erdal; Kose, Melis; Demircioglu, Sinan; Pekkolay, Zafer; Ilhan, Osman

doi:10.1016/j.atherosclerosis.2018.01.034

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)

Copy For Citation

KAYIKÇIOĞLU L. M., Tokgozoglu L., YILMAZ M. B., Kaynar L., Aktan M., Durmus R. B., ...More

ATHEROSCLEROSIS, vol.270, pp.42-48, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 270
Publication Date: 2018
Doi Number: 10.1016/j.atherosclerosis.2018.01.034
Journal Name: ATHEROSCLEROSIS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.42-48
Keywords: Lipoprotein apheresis, Homozygous familial hypercholesterolemia, Turkey, Registry, LIPOPROTEIN APHERESIS, FOLLOW-UP, DIAGNOSIS, INSIGHTS, THERAPY
Dokuz Eylül University Affiliated: No

Abstract

Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.